Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

By sjmartinez • April 19, 2024

Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024 Apr 17;190(5):668-679. doi: 10.1093/bjd/ljae014. PMID: 38226713.

Tags: Dermatology, Olive View DoM, Publications

Primary Cutaneous Melanoma Microbiome is Associated with Overall Survival and Recurrence

Chan AA, Noguti J, Ramirez NM, Navarrete M, Lee DJ. Primary Cutaneous Melanoma Microbiome is Associated with Overall Survival and Recurrence. J Invest Dermatol. 2025[...]

To Treat or Not to Treat: Two Roads Traveled With Alopecia Areata

Taghizadeh CS, Goh C. To Treat or Not to Treat: Two Roads Traveled With Alopecia Areata. Pediatr Dermatol. 2025 Aug 15. doi: 10.1111/pde.70006. Epub ahead[...]

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, Ochoa CJ, Singh T, DiBernardo G, Guo W, Li S, Zhou Y, Yu[...]